Brokerages predict that NxStage Medical, Inc. (NASDAQ:NXTM) will post earnings of ($0.02) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for NxStage Medical’s earnings. The lowest EPS estimate is ($0.05) and the highest is $0.02. NxStage Medical posted earnings of ($0.14) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 85.7%. The business is expected to issue its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that NxStage Medical will report full-year earnings of ($0.02) per share for the current year, with EPS estimates ranging from ($0.15) to $0.13. For the next fiscal year, analysts anticipate that the company will post earnings of $0.09 per share, with EPS estimates ranging from ($0.05) to $0.25. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $106.97 million during the quarter, compared to analyst estimates of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.
A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.
NxStage Medical stock traded down $0.05 during midday trading on Friday, reaching $28.98. 314,702 shares of the stock traded hands, compared to its average volume of 654,908. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -131.73 and a beta of -0.05. NxStage Medical has a fifty-two week low of $22.70 and a fifty-two week high of $29.19.
Large investors have recently modified their holdings of the company. NumerixS Investment Technologies Inc acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $122,000. Steward Partners Investment Advisory LLC lifted its stake in shares of NxStage Medical by 714.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after acquiring an additional 5,000 shares during the period. Keybank National Association OH acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $212,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $216,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of NxStage Medical in the 2nd quarter worth approximately $234,000. 83.15% of the stock is owned by institutional investors.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Featured Story: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.